Elevate Snapchill Coffee recalled over botulism concerns - Action News
Home WebMail Friday, November 22, 2024, 04:55 AM | Calgary | -13.8°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Health

Elevate Snapchill Coffee recalled over botulism concerns

A Canadian Food Inspection Agency spokesperson told CBC News that Friday's move was triggered when the U.S. Food and Drug Administration (FDA) informed the CFIA that the affected product was distributed in Alberta.

Product from Wisconsin-based company was distributed in Alberta

A combination images shows three photos of a canned drink being photographed from the front, back and bottom.
The Canadian Food Inspection Agency on Friday recalled the Elevate Snapchill Coffee product distributed by Alberta-basedEclipse Coffee Roaster. (Canadian Food Inspection Agency)

The Canadian Food Inspection Agency (CFIA) issued a recallof a canned coffee producton Friday over botulism concerns, a move that follows a similar action in the U.S.

The CFIA recall affects the Elevate Snapchill Coffee product distributed by in Canada by Alberta-basedEclipse Coffee Roaster. The product itself is made by Wisconsin-basedSnapchillcompany in the U.S.

"The affected product is being recalled from the marketplace because it may permit the growth of Clostridium botulinum," the CFIA said in a release.

TheClostridium botulinumbacteriacan, under certain conditions, produce a potentneurotoxinthat could lead to botulism.

"Food contaminated withClostridium botulinumtoxin may not look or smell spoiled but can still make you sick," the CFIA said. "In severe cases of illness, people may die."

TheElevate Snapchill Coffee product was voluntarily recalled in the U.S. by the company on June 17.

At the time, theU.S. Food and Drug Administration (FDA) saidSnapchill's low acid canned foods process for manufacturing the recalled products was not filed with the FDA, as is required by U.S. regulation.

A CFIA spokesperson told CBC News via email that Friday's move was "triggered when the[FDA]informed the CFIA that the affected product was distributed in Alberta."